Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

9,597

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

9,597 results for “transplantation”

Learn how ShareScore rates datasets ↗
zenodo36/100

Raw Data for the article: Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection

<p><strong>Background:</strong>&nbsp;Several studies have indicated that anti-SARS-CoV-2 mRNA vaccinations are less effective in inducing robust immune responses among solid organ transplant recipients (SOTRs) compared with the immunocompetent. The third dose of vaccine in SOTRs showed promising results of immunogenicity, even though clinical studies have suggested that immunocompromised subjects are less likely to build a protective immune response against SARS-CoV-2 resulting in lower vaccine efficacy for the prevention of severe COVID-19.&nbsp;<strong>Methods:</strong>&nbsp;Serological IgG and IgA were analyzed through CLIA or ELISA, respectively, while Spike-specific T cells were detected by ELISpot assay after the second and third dose of vaccine in 43 SOTRs.&nbsp;<strong>Results:</strong>&nbsp;The third dose induced an improvement in antibody response against SARS-CoV-2. We also reported a strong correlation between specific humoral and cellular responses after the third dose, even though we did not see significant changes in the magnitude of the SARS-CoV-2-specific T cell response. SOTRs who contracted the SARS-CoV-2 infection after the third dose, despite eliciting a positive IgG response, failed to mount an anti-Spike-S1 IgA response, both after the third dose and after SARS-CoV-2 infection.&nbsp;<strong>Conclusions:</strong>&nbsp;We can conclude that serum IgA detection can be helpful, along with IgG detection, for the evaluation of vaccine efficacy, principally in fragile subjects at high risk of infection.</p>

opencc-by-4.0Feb 2023View details →
zenodo36/100

Raw Data for the article: Clinical outcomes of transjugular intrahepatic portosystemic shunt with PTFE-covered stents after liver transplantation and technical results in split and whole liver graft recipients

<p><strong>Objectives:&nbsp;</strong>To assess the outcomes of transjugular intrahepatic portosystemic shunt (TIPS) creation using PTFE-covered stents in liver transplant (LT) recipients and to analyze the technical result of TIPS creation in split grafts (SG) compared with whole liver grafts (WG).</p> <p><strong>Methods and materials:&nbsp;</strong>Single-center, retrospective study, analyzing LT patients who underwent TIPS using PTFE-covered stents. Clinical and technical variables were analyzed.</p> <p><strong>Results:&nbsp;</strong>Between 2005 and 2021, TIPS was created using PTFE-covered stents in 48 LT patients at a median of 43 months (range, 0.5-192) after LT. TIPS indications were refractory ascites (RA) in 33 patients (69%), variceal bleeding (VB) in 9 patients (19%), others in 6 (12%). Ten patients (21%) received a SG. Technical success rate was 100% in both groups: in two WG recipients, (5%) a second attempt was required. An unconventional approach (combined transhepatic or transplenic access) was needed in 2 WG (5%) and 2 SG recipients (20%). Two procedure-related death occurred in the WG group. After a median follow-up of 22 months (range, 0,1-144), 16 patients (48%) in the RA group did not require post-TIPS paracentesis, in the VB group rebleeding occurred in 3 patients (33%). Fifteen patients (31%) underwent TIPS revision. Overt hepatic encephalopathy occurred in 14 patients (29%). Patient survival at 6 months, 1 year, and 3 years was 77%, 66%, and 43%, respectively.</p> <p><strong>Conclusions:&nbsp;</strong>The feasibility and safety of TIPS creation in SG are comparable to that of WG. TIPS creation using PTFE-covered stents represents a viable option to treat portal hypertensive complications in LT recipients.</p>

opencc-by-4.0Feb 2023View details →
zenodo36/100

Raw Data for the article: COVID-19 safety measures at the Radiology Unit of a Transplant Institute: the non-COVID-19 patient's confidence with safety procedures

<p><strong>Purpose:&nbsp;</strong>To support the wellbeing of both patients and their families, our aim was to investigate the satisfaction of non-COVID in- and out-patients regarding safety measures implemented at our radiology unit of a transplant institute against COVID infection.</p> <p><strong>Materials and methods:&nbsp;</strong>Over a five-month period, adult patients&#39; feedback was obtained by a questionnaire on the fear of contracting COVID-19 during a radiology examination, the perceived delay in treatment, and the following safety measures implemented: modified schedules to limit the number of patients in the waiting area and to maximize social distancing; assistance by staff when visitors were not admitted; cleaning and disinfection of machines; mask wearing and hand hygiene of staff; and staff advice on hand hygiene and infection control precautions.</p> <p><strong>Results:&nbsp;</strong>Over a five-month period, our preliminary results (387 patients) showed general patient satisfaction (99.1%) with safety measures applied at our radiology unit. Patients were satisfied with distancing and assistance by staff (100%), cleaning and disinfection (91%), mask wearing and hand hygiene of the staff (97%), and staff advice (94%). There was some criticism of the perceived delay in treatment (7.3%) and in the scheduling of the waiting list (5.4%), with 5.4% fearing contracting the virus. Patients&#39; awareness of safety measures and confidence in the hospital preparedness policy was perceived by all interviewers, and 100% appreciated being questioned.</p> <p><strong>Conclusion:&nbsp;</strong>The feedback given by the non-COVID patient helps to measure the quality in health care, to improve the quality service, and to protect and satisfy more vulnerable patients, also during the COVID-19 pandemic.</p>

opencc-by-4.0Feb 2023View details →
zenodo36/100

Raw Data for the article: Continuous Renal Replacement Therapy after Liver Transplantation: Peri-Operative Associated Factors and Impact on Survival

<p>Continuous renal replacement therapy (CRRT) following orthotopic liver transplantation (OLT) is usually started for multifactorial reasons, with variable incidence among series. This paper presents a single-center retrospective observational study on the early use (within one week) of CRRT after consecutive cadaveric OLT from January 2008 to December 2016. Preoperative patient characteristics and intraoperative data were collected, and patients were divided into two groups (CRRT and no CRRT) to explore the factors associated with the use of CRRT. Repeated measurements of postoperative creatinine were analyzed with generalized estimating equation (GEE) models. Among 528 OLT patients, 75 (14.2%) were treated with CRRT at least once in the first week. Patients treated with CRRT showed lower survival in a Kaplan-Meier curve (log-rank&nbsp;<em>p</em>&nbsp;value &amp;lt; 0.01). Patients treated with CRRT had a more severe preoperative profile, with a significantly higher age, MELD, BUN, creatinine, and total bilirubin, as well as a longer surgery time and a higher number of transfusions of red blood cells, plasma, and platelets (all&nbsp;<em>p</em>&nbsp;values &amp;lt; 0.05). In a stepwise multiple analysis, the following characteristics remained independently associated with the use of CRRT: the MELD score OR 1.12 (95% CL: 1.07-1.16),&nbsp;<em>p</em>&nbsp;value &amp;lt; 0.001, and the preoperative value for blood urea nitrogen OR 1.016 (95% CL: 1.010-1.023),&nbsp;<em>p</em>&nbsp;value &amp;lt; 0.001. The early use of CRRT after OLT occurred at a low rate in this large cohort; however, it was associated with worse outcomes. Apart from the preoperative severity, repeated intraoperative hypotension episodes, which were likely modifiable or preventable, were associated with the increased use of CRRT and higher postoperative creatinine.</p>

opencc-by-4.0Feb 2023View details →
zenodo36/100

Raw Data for the article: How important is the role of iterative liver direct surgery in patients with hepatocellular carcinoma for a transplant center located in an area with a low rate of deceased donation?

<p><strong>Introduction:&nbsp;</strong>Hepatocellular carcinoma (HCC) accounts for nearly 90% of primary liver cancers, with estimates of over 1 million people affected by 2025. We aimed to explore the impacting role of an iterative surgical treatment approach in a cohort of HCC patients within the Milan criteria, associated with clinical risk factors for tumor recurrence (RHCC) after liver transplant (LT) and loco-regional therapies (LRT), as well as liver resection (LR) and/or microwave thermal ablation (MWTA).</p> <p><strong>Methods:&nbsp;</strong>We retrospectively analyzed our experience performed during an 8-year period between January 2013 and December 2021 in patients treated for HCC, focusing on describing the impact on preoperative end-stage liver disease severity, oncologic staging, tumor characteristics, and surgical treatments. The Cox model was used to evaluate variables that could predict relapse risks. Relapse risk curves were calculated according to the Kaplan-Meier method, and the log-rank test was used to compare them.</p> <p><strong>Results:&nbsp;</strong>There were 557 HCC patients treated with a first-line approach of LR and/or LRTs (<em>n</em>&nbsp;= 335) or LT (<em>n</em>&nbsp;= 222). The median age at initial transplantation was 59 versus 68 for those whose first surgical approach was LR and/or LRT. In univariate analysis with the Cox model, nodule size was the single predictor of recurrence of HCC in the posttreatment setting (HR: 1.61, 95% CI: 1.05-2.47,&nbsp;<em>p</em>&nbsp;= 0.030). For the LRT group, we have enlightened the following clinical characteristics as significantly associated with RHCC: hepatitis B virus infection (which has a protective role with HR: 0.34, 95% CI: 0.13-0.94,&nbsp;<em>p</em>&nbsp;= 0.038), number of HCC nodules (HR: 1.54, 95% CI: 1.22-1.94,&nbsp;<em>p</em>&nbsp;&lt; 0.001), size of the largest nodule (HR: 1.06, 95% CI: 1.01-1.12,&nbsp;<em>p</em>&nbsp;= 0.023), serum bilirubin (HR: 1.57, 95% CI: 1.03-2.40,&nbsp;<em>p</em>&nbsp;= 0.038), and international normalized ratio (HR: 16.40, 95% CI: 2.30-118.0,&nbsp;<em>p</em>&nbsp;= 0.006). Among the overall 111 patients with RHCC in the LRT group, 33 were iteratively treated with further curative treatment (12 were treated with LR, two with MWTA, three with a combined LR-MWTA treatment, and 16 underwent LT). Only one of 18 recurrent patients previously treated with LT underwent LR. For these RHCC patients, multivariable analysis showed the protective roles of LT for primary RHCC after IDLS (HR: 0.06, 95% CI: 0.01-0.36,&nbsp;<em>p</em>&nbsp;= 0.002), of the time relapsed between the first and second IDLS treatments (HR: 0.97, 95% CI: 0.94-0.99,&nbsp;<em>p</em>&nbsp;= 0.044), and the impact of previous minimally invasive treatment (HR: 0.28, 95% CI: 0.08-1.00,&nbsp;<em>p</em>&nbsp;= 0.051).</p> <p><strong>Conclusion:&nbsp;</strong>The coexistence of RHCC with underlying cirrhosis increases the complexity of assessing the net health benefit of ILDS before LT. Minimally invasive surgical therapies and time to HCC relapse should be considered an outcome in randomized clinical trials because they have a relevant impact on tumor-free survival.</p>

opencc-by-4.0Feb 2023View details →
dryad36/100

Methods of species pool determination as predictors of survival in seeding and transplanting experiments

<ol> <li><span>Community composition is limited by a species' ability to reach, establish, and survive on a site. Establishment and survival are constrained by both abiotic conditions and biotic interactions that operate together on local scales. They decide which species from the pool will form the community. For this reason, it is very important to clearly define the species pool, against which the community composition is compared. </span></li> <li><span>The effect of biotic and abiotic factors can be assessed experimentally, and the species pool by using estimation methods based on broad-scale observational data. We compared success of five species pool estimation methods in predicting establishment and survival in a seed/transplant addition experiment. </span></li> <li> <span>In four different locations, we added resident and non-resident species to plots with and without competition and</span><span> tested the ability of the species to thrive in both competition-free gaps (constrained mainly by abiotic conditions) and in intact vegetation (complete community filter). In these treatments, we studied the seedling recruitment and survival, and the establishment and survival of pre-grown transplants. The ability of species pool assessment methods to predict species performance in individual treatments was compared. The comparison of results from individual treatments indicates the importance of individual components of the community filter. </span> </li> <li><span>Species pool assessment methods, based on species co-occurrence patterns (Beals index, Favourability, and Unconstrained ordination), were the best predictors of species performance in the intact vegetation but were less successful in the competition-free environment. Methods based on co-occurrence patterns were the most effective for predicting seedling establishment, while seed germination alone and transplant survival were poorly predictable. </span></li> <li><span>The biotic filter was the principal factor defining our community composition, especially for the process of seedling establishment. The roles of biotic and abiotic filters are very difficult to distinguish without an experimental approach and the ratio of their importance changes during plant ontogenesis.</span></li> </ol>

opencc-zeroMay 2023View details →
dryad36/100

Increased eye size is favoured in Trinidadian killifish experimentally transplanted into low light, high competition environments

<p>Intraspecific <span>variation in vertebrate eye size is well known. Ecological factors such as light availability are often correlated with shifts in relative eye size. However, experimental tests of selection on eye size are lacking. Trinidadian killifish (<em>Anablepsoides hartii</em>) are found in sites that differ in predation intensity. Sites that lack predators are characterized by lower light, high killifish densities, low resource availability, and intense competition for food. We previously found that killifish in sites that lack predators have evolved a larger relative eye size than fish from sites with predators. Here we used transplant experiments to test how selection operates on eye size when fish that are adapted to sites with predators are translocated into sites where predators are absent. We observed a significant 'population x relative eye size' interaction; the relationship between relative eye size and a proxy for fitness (rates of individual growth) was positive in the transplanted fish. The trend was opposite for resident fish. Such results provide experimental support that larger eyes enhance fitness and are favoured in environments characterized by low light and high competition.</span></p>

opencc-zeroMay 2023View details →
zenodo36/100

Epiphytic bryophyte and lichen transplant dataset, Oregon, USA

<p>This dataset consist of epiphytic bryophyte and lichen transplants, which were transplanted along elevation gradient in Oregon, USA in 2010. The data is part of the publication: &quot;Epiphytic bryophyte and lichen transplant niches in changed environments along an elevational gradient in Pacific Northwest conifer forests&quot;. The data were collected with a financial support of&nbsp;&nbsp;Fulbright Scholar programme 2009/2010 and processed with a financial support of&nbsp; postdoctoral grant &ldquo;Epiphyte metapopulation dynamics in boreo-nemoral forest landscape&rdquo; (Nr. 1.1.1.2/VIAA/3/19/469).</p>

opencc-by-4.0May 2023View details →
zenodo36/100

Rational Modification of Human Gut Microbial Metabolites by Dietary Resistant Starch in Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Feasibility Study

<p>We conducted a prospective longitudinal feasibility study in patients undergoing allo-HCT for hematological malignancies to test the hypothesis that defined and consistent administration of resistant starch will rationally modify intestinal microbiota dependent metabolites, particularly the short chain fatty acids (SCFA), such as butyrate.&nbsp; Ten adults undergoing human leukocyte antigen-matched, related-donor myeloablative allo-HCT were enrolled and received resistant potato starch (RPS) daily from day -7 to day 100 after allo-HCT.&nbsp;</p>

opencc-by-3.0-usApr 2023View details →
zenodo36/100

[Data S10] Microbiota dictate T cell clonal selection to promote graft-vs-host disease after stem cell transplantation

<p>Data S10. 10x genomics sequencing data files for Figure 5. Matrix file &quot;sample_filtered_feature_bc_matrix.h5&quot; and V(D)J annotations &quot;filtered_contig_annotations.csv&quot; are included below. Accompanying code can be found at https://github.com/acyeh-lab/2023/tree/main/scseq.</p>

opencc-by-4.0Jun 2023View details →
ClinicalTrials.gov36/100

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

ClinicalTrials.gov study NCT02981914. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma

ClinicalTrials.gov study NCT02416206. IPD Sharing: Not stated. Countries: 1. Publications: 26.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

ClinicalTrials.gov study NCT00047320. IPD Sharing: Not stated. Countries: 5. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting

ClinicalTrials.gov study NCT02350569. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

ClinicalTrials.gov study NCT05706766. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

ClinicalTrials.gov study NCT01690143. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remis

ClinicalTrials.gov study NCT00382109. IPD Sharing: Not stated. Countries: 3. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

ClinicalTrials.gov study NCT00559104. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

ClinicalTrials.gov study NCT02100891. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Hyperglycemia in Renal Transplantation

ClinicalTrials.gov study NCT01643382. IPD Sharing: Not stated. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record